Oncogene addiction and tumor mutational burden in non‐small‐cell lung cancer: Clinical significance and limitations
Abstract Lung cancer incidence has increased worldwide over the past decades, with non‐small cell lung cancer (NSCLC) accounting for the vast majority (85%) of lung cancer specimens. It is estimated that lung cancer causes about 1.7 million global deaths per year worldwide. Multiple trials have been...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-02-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.13246 |
| _version_ | 1819069613399343104 |
|---|---|
| author | Elisabeth Smolle Katharina Leithner Horst Olschewski |
| author_facet | Elisabeth Smolle Katharina Leithner Horst Olschewski |
| author_sort | Elisabeth Smolle |
| collection | DOAJ |
| description | Abstract Lung cancer incidence has increased worldwide over the past decades, with non‐small cell lung cancer (NSCLC) accounting for the vast majority (85%) of lung cancer specimens. It is estimated that lung cancer causes about 1.7 million global deaths per year worldwide. Multiple trials have been carried out, with the aim of finding new effective treatment options. Lately, special focus has been placed on immune checkpoint (PD1/PD‐L1) inhibitors which impact the tumor immune microenvironment. Tumor mutational burden (TMB) has been found to predict response to immune checkpoint inhibitors. Conversely, recent studies have weakened the significance of TMB as a predictor of response to therapy and survival. In this review article, we discuss the significance of TMB, as well as possible limitations. Furthermore, we give a concise overview of mutations frequently found in NSCLC, and discuss the significance of oncogene addiction in lung cancer as an essential driver of tumorigenesis and tumor progression. |
| first_indexed | 2024-12-21T16:52:50Z |
| format | Article |
| id | doaj.art-8c93ccc453e042b4aca3e93e9e190660 |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-12-21T16:52:50Z |
| publishDate | 2020-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-8c93ccc453e042b4aca3e93e9e1906602022-12-21T18:56:49ZengWileyThoracic Cancer1759-77061759-77142020-02-0111220521510.1111/1759-7714.13246Oncogene addiction and tumor mutational burden in non‐small‐cell lung cancer: Clinical significance and limitationsElisabeth Smolle0Katharina Leithner1Horst Olschewski2Division of Pulmonology, Department of Internal Medicine Medical University of Graz Graz AustriaDivision of Pulmonology, Department of Internal Medicine Medical University of Graz Graz AustriaDivision of Pulmonology, Department of Internal Medicine Medical University of Graz Graz AustriaAbstract Lung cancer incidence has increased worldwide over the past decades, with non‐small cell lung cancer (NSCLC) accounting for the vast majority (85%) of lung cancer specimens. It is estimated that lung cancer causes about 1.7 million global deaths per year worldwide. Multiple trials have been carried out, with the aim of finding new effective treatment options. Lately, special focus has been placed on immune checkpoint (PD1/PD‐L1) inhibitors which impact the tumor immune microenvironment. Tumor mutational burden (TMB) has been found to predict response to immune checkpoint inhibitors. Conversely, recent studies have weakened the significance of TMB as a predictor of response to therapy and survival. In this review article, we discuss the significance of TMB, as well as possible limitations. Furthermore, we give a concise overview of mutations frequently found in NSCLC, and discuss the significance of oncogene addiction in lung cancer as an essential driver of tumorigenesis and tumor progression.https://doi.org/10.1111/1759-7714.13246Mutational burdennon‐small cell lung canceroncogene addiction |
| spellingShingle | Elisabeth Smolle Katharina Leithner Horst Olschewski Oncogene addiction and tumor mutational burden in non‐small‐cell lung cancer: Clinical significance and limitations Thoracic Cancer Mutational burden non‐small cell lung cancer oncogene addiction |
| title | Oncogene addiction and tumor mutational burden in non‐small‐cell lung cancer: Clinical significance and limitations |
| title_full | Oncogene addiction and tumor mutational burden in non‐small‐cell lung cancer: Clinical significance and limitations |
| title_fullStr | Oncogene addiction and tumor mutational burden in non‐small‐cell lung cancer: Clinical significance and limitations |
| title_full_unstemmed | Oncogene addiction and tumor mutational burden in non‐small‐cell lung cancer: Clinical significance and limitations |
| title_short | Oncogene addiction and tumor mutational burden in non‐small‐cell lung cancer: Clinical significance and limitations |
| title_sort | oncogene addiction and tumor mutational burden in non small cell lung cancer clinical significance and limitations |
| topic | Mutational burden non‐small cell lung cancer oncogene addiction |
| url | https://doi.org/10.1111/1759-7714.13246 |
| work_keys_str_mv | AT elisabethsmolle oncogeneaddictionandtumormutationalburdeninnonsmallcelllungcancerclinicalsignificanceandlimitations AT katharinaleithner oncogeneaddictionandtumormutationalburdeninnonsmallcelllungcancerclinicalsignificanceandlimitations AT horstolschewski oncogeneaddictionandtumormutationalburdeninnonsmallcelllungcancerclinicalsignificanceandlimitations |